Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Huang on Research in ALK+ NSCLC

April 26th 2022

Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.

Adjuvant Atezolizumab Approaches EU Approval for High-Risk NSCLC With PD-L1 of ≥50%

April 22nd 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of adjuvant atezolizumab, after complete resection and platinum-based chemotherapy, in adult patients with non–small cell lung cancer with a high risk of recurrence and whose tumors express PD-L1 of 50% or higher and do not harbor EGFR mutations or ALK alterations.

Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

April 22nd 2022

Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.

Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

April 22nd 2022

Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer

April 21st 2022

The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer.

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

April 20th 2022

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

Challenges Associated with Molecular Testing in NSCLC

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

FDA Grants Priority Review to Trastuzumab Deruxtecan for Previously Treated HER2-Mutant NSCLC

April 19th 2022

The FDA has accepted for priority review a supplemental biologics license application for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have a HER2 mutation and who have received a prior systemic therapy.

Frontline Therapy Advances Are Current Focus in SCLC and NSCLC

April 18th 2022

Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.

Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

April 15th 2022

Meghan Mooradian, MD, highlights best practices for identifying molecular alterations in NSCLC and addresses barriers to testing.

Overview of Actionable Mutations and Molecular Profiling in NSCLC

April 15th 2022

Expert perspective on the current landscape of actionable mutations and molecular profiling in non–small cell lung cancer management.

Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives

April 14th 2022

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.

Adebrelimab Plus Chemotherapy Improves Survival Vs Chemotherapy Alone in ES-SCLC

April 13th 2022

The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.

Frontline Canakinumab Triplet Misses Mark in Advanced NSCLC, But Shows Benefit in Select Subsets

April 13th 2022

The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.

SCC244 Elicits Responses in METex14 Skipping–Mutated NSCLC

April 12th 2022

SCC244, a highly selective MET inhibitor, demonstrated durable efficacy in patients with non–small cell lung cancer who harbored MET exon 14 skipping mutations.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC

April 11th 2022

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC

April 11th 2022

The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.